-
Since 2022, a large number of pharmaceutical companies have joined the team to sell assets
Time of Update: 2022-05-02
For example, in mid-February, some industry sources said that Sandoz, a generic drug company owned by Novartis, may be sold to private equity firms Blackstone Group and Carlyle Group for $25 billion.
-
Another pharmaceutical company discloses 2021 annual performance forecast
Time of Update: 2022-05-02
The performance forecast released by GenScript Biotechnology shows that in fiscal 2021, the adjusted net profit of the group business (non-cell therapy business) excluding the subsidiary Legend Biotechnology was about US$48 million to US$51.
-
More than 240 pharmaceutical companies have disclosed performance forecasts, with dazzling net profits concentrated in the fields of vaccines and testing
Time of Update: 2022-05-02
. In addition to Zhifei Bio and CanSino, the net profit of vaccine companies such as Olin Bio and Kangtai Bio is also expected to increase significantly year-on-year in 2021.
-
Pharmaceutical companies are in hot pursuit of innovation and R&D, with more than 20 new applications for Category 1 drug trials added within a week
Time of Update: 2022-05-02
Coincidentally, the marketing application of the new anti-tumor drug MET inhibitor Gumetinib, jointly developed by Haihe Pharmaceuticals and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, has also been accepted by the State Food and Drug Administration and is being announced for priority review .
-
The abuse of antibiotics at the grassroots level is more than the harm of the abuse of antibiotics?
Time of Update: 2022-05-02
Moxifloxacin, as a fourth-generation quinolone broad-spectrum antibacterial drug, has been mainly used in large hospitals for patients with pulmonary infection in recent years, that is, when ordinary antibiotics are ineffective .
But this patient was only on moxifloxacin for a common upper respiratory tract infection .
-
Dozens of executives of pharmaceutical companies have left this year, and traditional Chinese medicine companies account for the majority
Time of Update: 2022-05-02
According to the report, Li Weijun applied to resign as the company's director, vice president and member of the compensation and appraisal committee of the board of directors due to personal reasons, and at the same time resigned from all positions held in the company's subsidiaries .
-
Pharmaceutical companies are strengthening domestic substitution of upstream equipment, and the pharmaceutical machine industry may benefit
Time of Update: 2022-05-02
For this cooperation, the industry believes that, in addition to speeding up the integrated competitiveness of the research and development, production and sales of Kangfang biopharmaceuticals, it is also a manifestation of domestic innovative pharmaceutical companies strengthening the independent controllability of the supply chain and domestic substitution .
-
More than 900 companies were investigated, and 2 pharmaceutical machine companies received attention from more than 20 institutions
Time of Update: 2022-05-02
Among them, in view of the company's future business growth, Chutian Technology said that three years ago, the company has been deploying import substitution in the high-end market of vaccine products, and product performance and quality have been able to meet the needs of high-end customers .
-
The policy of speeding up the evaluation of new traditional Chinese medicines has detonated the market conditions, and the battle for innovative resources of traditional Chinese medicines has begun!
Time of Update: 2022-05-02
The "Guiding Opinions of the National Medical Security Administration and the State Administration of Traditional Chinese Medicine on Medical Insurance Supporting the Inheritance, Innovation and Development of Traditional Chinese Medicine" is one of the important factors that will detonate the performance of the entire traditional Chinese medicine industry in the secondary market by the end of 2021 and early 2022 .
-
Intellia and Regeneron Announce Latest Phase 1 Clinical Trial Data of NTLA-2001
Time of Update: 2022-05-02
The results showed that all doses administered were well tolerated, with mean 86% and 93% reductions in serum levels of the target protein in the two highest dose groups, respectively .
-
The centralized procurement of dental implants is already in the air, will the price be greatly reduced in the future?
Time of Update: 2022-05-02
After the National Medical Insurance Bureau clarified the centralized procurement of dental implants, the market has also expressed concern about the attitude of related dental companies .
-
78 drugs from 21 pharmaceutical companies took the initiative to cut prices, with a drop of over 60%!
Time of Update: 2022-05-02
On February 21, the Yunnan Provincial Centralized Drug Purchasing Platform issued a public announcement about companies applying for price reductions .
7ml:100mg and 5ml:30mg specifications of Huiyu Pharmaceutical's paclitaxel injection have been greatly reduced in price, of which the 16.
-
Antibacterial preparations illegally added to drugs?
Time of Update: 2022-05-02
For these outstanding problems, the Supreme People's Procuratorate requires, on the one hand, to urge the drug safety supervision department to perform its supervision and management duties in accordance with the law through administrative public interest litigation; Violators are liable for punitive damages, making them so painful that they dare not commit the crime again .
-
Kelun Pharmaceutical Holdings subsidiary SKB378/HBM9378 injection obtained clinical trial notice
Time of Update: 2022-05-02
On February 21, Kelun Pharmaceutical issued an announcement saying that the SKB378/HBM9378 injection jointly developed by its holding subsidiary Kelun Botai and Hebo Pharmaceutical obtained the clinical trial notice from the State Drug Administration, agreeing to carry out moderate-to-severe clinical trials for this product.
-
With frequent personnel changes, domestic pharmaceutical companies have ushered in major adjustments
Time of Update: 2022-05-02
For example, on February 23, Guangshengtang announced that the company recently appointed George Zhang (Zhang Yuhua) as the company's innovative drug holding subsidiary Fujian Guangsheng Zhonglin Biotechnology Co.
-
Kexing Pharmaceutical's 2021 performance: total revenue of 1.285 billion yuan, a year-on-year increase of 5.31%
Time of Update: 2022-05-02
285 billion yuan in 2021, a year-on-year increase of 5.
31%; net profit attributable to owners of the parent company is 90 million yuan, a year-on-year decrease of 35.
45 yuan, a year-on-year decrease of 51.
83%, a year-on-year decrease of 13.
-
Shanghai Suspends Xinfeng Pharmaceutical's Procurement Qualification for Luotongding Sulfate Injection for 1 Year
Time of Update: 2022-05-02
On February 24, 2022, the Shanghai Pharmaceutical Centralized Tendering and Procurement Administration issued a notice on the suspension of the procurement qualification of Luotongdine Sulfate Injection produced by Guangdong Xinfeng Pharmaceutical Co.
51), the procurement qualification of Luotongding Sulfate Injection produced by Guangdong Xinfeng Pharmaceutical Co.
-
Fangsheng Pharmaceutical will transfer part of the equity of its holding subsidiary and introduce strategic investors
Time of Update: 2022-05-02
On February 28, Fangsheng Pharmaceutical issued an announcement stating that the third extraordinary meeting of the fifth session of the board of directors of the company in 2022 reviewed and approved the "Proposal on the Transfer of Partial Equity Delivery of the Holding Subsidiary", agreeing that the company and DeVita, Baijun Medical, Kanglai Health, Ruijian Health, and Changsha Baijun signed the Supplementary Agreement (II) to the Convertible Bond Agreement on the issue of loans issued by DeVita Company .
-
Ge Lei, Securities Representative of Watson Pharmaceuticals, resigns
Time of Update: 2022-05-02
On February 22, Watson Pharmaceuticals issued an announcement stating that Ge Lei resigned from the position of the company's securities affairs representative due to personal reasons.
The resignation letter took effect from the day it was served on the company's board of directors .
-
Can Shimai Pharmaceutical get hundreds of millions of financing again to stir up the tens of billions of anti-dumping rivers and lakes?
Time of Update: 2022-05-02
According to reports, the company's world's first EGFR/CD3 bispecific antibody has recently been approved for clinical use, which is expected to become a major breakthrough in the treatment of CD3 dual antibodies from hematological tumors to solid tumors .
